CINV Existing and Pipeline Drugs Market – Global Industry Analysis and forecast (2023 – 2029)


CINV Existing and Pipeline Drugs Market is expected to reach US$ 2.17 Bn. at a CAGR of 4.9 during the forecast period 2029.

CINV Existing and Pipeline Drugs Market Drivers and Restrains

Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV). Rising prevalence of various types of cancer is fueling the growth of Global CINV Existing and Pipeline Drugs Market during forecast period.Global CINV Existing and Pipeline Drugs MarketTo know about the Research Methodology :- Request Free Sample Report

Technological advances for invention of new drugs are driving global market. Chemotherapy has helped millions of people in their battle against cancer, also chemotherapy supports to destroy cancer cells. Unfortunately, healthy noncancerous cells are sometimes destroyed and this can lead to unpleasant side effects this may cause major restraint to Global CINV Existing and Pipeline Drugs Market.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.

CINV Existing and Pipeline Drugs Market key segmentation

Global CINV Existing and Pipeline Drugs Market is segmented into By Drug type and By End-use. Based on Drug Type the market is categorized in to Akynzeo (netupitant-palonosetron), Emend (aprepitant), Aloxi (palonosetron), Zofran Generic (ondansetron), Kytril Generic (granisetron), SUSTOL (extended release granisetron injection), Rolapitant. Among these Aloxi is expected lucrative share of global market as this drug is known as a second-generation serotonin receptor blocker.

In most situations, these drugs are very safe to take and have minimal side effects. Based on By End-use the global market is divided in to Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies, and Drugstores. Among these hospitals segment emerged as the fastest growing segment during forecast period. Rising patient population is responsible for this segmental growth.

CINV Existing and Pipeline Drugs Market Regional Analysis

Based on region Global CINV Existing and Pipeline Drugs Market is segmented in to Asia Pacific, North America, Europe, Latin America, and Middle East Africa. Among these North America holds the largest share of Global CINV Existing and Pipeline Drugs Market in 2018. Because of approval of rolapitant and Sustol drugs the market is growing with significant CAGR of xx% during forecast period. Europe emerged as the second largest market for CINV drugs after North America in 2018.

The launch of CINV pipeline drugs in Europe is expected to be a year later than in North America, given the delays on the past launches of CINV drugs such as Aloxi and Emend. Asia-Pacific is expected to grow with moderate CAGR of xx% during forecast period , the rising incidences of various types of cancer is responsible for increased growth rate in this region.

The objective of the report is to present comprehensive analysis of Global CINV Existing and Pipeline Drugs Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region.

PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding Global CINV Existing and Pipeline Drugs Market dynamics, structure by analyzing the market segments, and project the Global CINV Existing and Pipeline Drugs Market size. Clear representation of competitive analysis of key players by Thyroid Gland Disorders Treatment Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global CINV Existing and Pipeline Drugs Market make the report investor’s guide.

Scope of Global CINV Existing and Pipeline Drugs Market: Inquire before buying






Global CINV Existing and Pipeline Drugs Market




Report Coverage
Details




Base Year:
2022
Forecast Period:
2023-2029




Historical Data:
2017 to 2022
Market Size in 2022:
US $ 1.55 Bn.




Forecast Period 2023 to 2029 CAGR:
4.9%
Market Size in 2029:
US $ 2.17 Bn.




 Segments Covered:
by Drug Type
• Akynzeo (netupitant-palonosetron),
• Emend (aprepitant),
• Aloxi (palonosetron),
• Zofran Generic (ondansetron),
• Kytril Generic (granisetron),
• SUSTOL (extended release granisetron injection),
• Rolapitant




by End Use
• Hospitals
• Specialty Clinics
• Diagnostic Centers Therapeutics
• Hospital Pharmacies
• Drugstores






CINV Existing and Pipeline Drugs Market, by Region

• North America (United States, Canada and Mexico)
• Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
• Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
• Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
• South America (Brazil, Argentina Rest of South America)

CINV Existing and Pipeline Drugs Market, Key Players are:

• GlaxoSmithKline
• Helsinn
• Heron Therapeutics
• Merck
• Tesaro
• Eastman
• Lonza
• CHEMIDEA CHEMICALS
• Teva pharmaceutical
• Baxter Healthcare,
• Sun Pharma,
• Mylan Pharmaceuticals, Inc.,
• Sandoz (Novartis AG),
• Barr Laboratories, Inc.
• Orchid Healthcare
• Acacia Pharma
• TALLC Corporation
• LP Pharmaceuticals

Frequently Asked Questions:

1. Which region has the largest share in Global CINV Existing and Pipeline Drugs Market?
Ans: Asia Pacific region held the highest share in 2022.

2. What is the growth rate of Global CINV Existing and Pipeline Drugs Market?
Ans: The Global CINV Existing and Pipeline Drugs Market is growing at a CAGR of 4.9% during forecasting period 2023-2029.

3. What is scope of the Global CINV Existing and Pipeline Drugs Market report?
Ans: Global CINV Existing and Pipeline Drugs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global CINV Existing and Pipeline Drugs Market?
Ans: The important key players in the Global CINV Existing and Pipeline Drugs Market are – GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck, Tesaro, Eastman, Lonza, CHEMIDEA CHEMICALS, Teva pharmaceutical, Baxter Healthcare,, Sun Pharma,, Mylan Pharmaceuticals, Inc.,, Sandoz (Novartis AG),, Barr Laboratories, Inc., Orchid Healthcare, Acacia Pharma, TALLC Corporation, LP Pharmaceuticals.

5. What is the study period of this Market?
Ans: The Global CINV Existing and Pipeline Drugs Market is studied from 2022 to 2029. 




Global CINV Existing and Pipeline Drugs Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global CINV Existing and Pipeline Drugs Market Size, by Market Value (US$ Bn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
4.8. Patent Registration

5. Supply Side and Demand Side Indicators
6. Global CINV Existing and Pipeline Drugs Market Analysis and Forecast
6.1. Global CINV Existing and Pipeline Drugs Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global CINV Existing and Pipeline Drugs Market Analysis and Forecast, By Drug type
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global CINV Existing and Pipeline Drugs Market Value Share Analysis, By Drug type
7.4. Global CINV Existing and Pipeline Drugs Market Size (US$ Bn) Forecast, By Drug type
7.5. Global CINV Existing and Pipeline Drugs Market Analysis, By Drug type
7.6. Global CINV Existing and Pipeline Drugs Market Attractiveness Analysis, By Drug type

8. Global CINV Existing and Pipeline Drugs Market Analysis and Forecast, By End-Use
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global CINV Existing and Pipeline Drugs Market Value Share Analysis, By End-Use
8.4. Global CINV Existing and Pipeline Drugs Market Size (US$ Bn) Forecast, By End-Use
8.5. Global CINV Existing and Pipeline Drugs Market Analysis, By End-Use
8.6. Global CINV Existing and Pipeline Drugs Market Attractiveness Analysis, By End-Use

9. Global CINV Existing and Pipeline Drugs Market Analysis, by Region
9.1. Global CINV Existing and Pipeline Drugs Market Value Share Analysis, by Region
9.2. Global CINV Existing and Pipeline Drugs Market Size (US$ Bn) Forecast, by Region
9.3. Global CINV Existing and Pipeline Drugs Market Attractiveness Analysis, by Region

10. North America CINV Existing and Pipeline Drugs Market Analysis
10.1. Key Findings
10.2. North America CINV Existing and Pipeline Drugs Market Overview
10.3. North America CINV Existing and Pipeline Drugs Market Value Share Analysis, By Drug type
10.4. North America CINV Existing and Pipeline Drugs Market Forecast, By Drug type
10.4.1. Akynzeo (netupitant-palonosetron),
10.4.2. Emend (aprepitant),
10.4.3. Aloxi (palonosetron),
10.4.4. Zofran Generic (ondansetron),
10.4.5. Kytril Generic (granisetron),
10.4.6. SUSTOL (extended release granisetron injection),
10.4.7. Rolapitant
10.5. North America CINV Existing and Pipeline Drugs Market Value Share Analysis, By End-Use
10.6. North America CINV Existing and Pipeline Drugs Market Forecast, By End-Use
10.6.1. Hospitals
10.6.2. Specialty Clinics
10.6.3. Diagnostic Centers Therapeutics
10.6.4. Hospital Pharmacies
10.6.5. Drugstores
10.7. North America CINV Existing and Pipeline Drugs Market Value Share Analysis, by Country
10.8. North America CINV Existing and Pipeline Drugs Market Forecast, by Country
10.8.1. U.S.
10.8.2. Canada
10.9. North America CINV Existing and Pipeline Drugs Market Analysis, by Country
10.10. U.S. CINV Existing and Pipeline Drugs Market Forecast, By Drug type
10.10.1. Akynzeo (netupitant-palonosetron),
10.10.2. Emend (aprepitant),
10.10.3. Aloxi (palonosetron),
10.10.4. Zofran Generic (ondansetron),
10.10.5. Kytril Generic (granisetron),
10.10.6. SUSTOL (extended release granisetron injection),
10.10.7. Rolapitant
10.11. U.S. CINV Existing and Pipeline Drugs Market Forecast, By End-Use
10.11.1. Hospitals
10.11.2. Specialty Clinics
10.11.3. Diagnostic Centers Therapeutics
10.11.4. Hospital Pharmacies
10.11.5. Drugstores
10.12. Canada CINV Existing and Pipeline Drugs Market Forecast, By Drug type
10.12.1. Akynzeo (netupitant-palonosetron),
10.12.2. Emend (aprepitant),
10.12.3. Aloxi (palonosetron),
10.12.4. Zofran Generic (ondansetron),
10.12.5. Kytril Generic (granisetron),
10.12.6. SUSTOL (extended release granisetron injection),
10.12.7. Rolapitant
10.13. Canada CINV Existing and Pipeline Drugs Market Forecast, By End-Use
10.13.1. Hospitals
10.13.2. Specialty Clinics
10.13.3. Diagnostic Centers Therapeutics
10.13.4. Hospital Pharmacies
10.13.5. Drugstores
10.14. North America CINV Existing and Pipeline Drugs Market Attractiveness Analysis
10.14.1. By Drug type
10.14.2. By End-Use
10.15. PEST Analysis
10.16. Key Trends
10.17. Key Development

11. Europe CINV Existing and Pipeline Drugs Market Analysis
11.1. Key Findings
11.2. Europe CINV Existing and Pipeline Drugs Market Overview
11.3. Europe CINV Existing and Pipeline Drugs Market Value Share Analysis, By Drug type
11.4. Europe CINV Existing and Pipeline Drugs Market Forecast, By Drug type
11.4.1. Akynzeo (netupitant-palonosetron),
11.4.2. Emend (aprepitant),
11.4.3. Aloxi (palonosetron),
11.4.4. Zofran Generic (ondansetron),
11.4.5. Kytril Generic (granisetron),
11.4.6. SUSTOL (extended release granisetron injection),
11.4.7. Rolapitant
11.5. Europe CINV Existing and Pipeline Drugs Market Value Share Analysis, By End-Use
11.6. Europe CINV Existing and Pipeline Drugs Market Forecast, By End-Use
11.6.1. Hospitals
11.6.2. Specialty Clinics
11.6.3. Diagnostic Centers Therapeutics
11.6.4. Hospital Pharmacies
11.6.5. Drugstores
11.7. Europe CINV Existing and Pipeline Drugs Market Value Share Analysis, by Country
11.8. Europe CINV Existing and Pipeline Drugs Market Forecast, by Country
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Rest of Europe
11.9. Europe CINV Existing and Pipeline Drugs Market Analysis, by Country
11.10. Germany CINV Existing and Pipeline Drugs Market Forecast, By Drug type
11.10.1. Akynzeo (netupitant-palonosetron),
11.10.2. Emend (aprepitant),
11.10.3. Aloxi (palonosetron),
11.10.4. Zofran Generic (ondansetron),
11.10.5. Kytril Generic (granisetron),
11.10.6. SUSTOL (extended release granisetron injection),
11.10.7. Rolapitant
11.11. Germany CINV Existing and Pipeline Drugs Market Forecast, By End-Use
11.11.1. Hospitals
11.11.2. Specialty Clinics
11.11.3. Diagnostic Centers Therapeutics
11.11.4. Hospital Pharmacies
11.11.5. Drugstores
11.12. U.K. CINV Existing and Pipeline Drugs Market Forecast, By Drug type
11.12.1. Akynzeo (netupitant-palonosetron),
11.12.2. Emend (aprepitant),
11.12.3. Aloxi (palonosetron),
11.12.4. Zofran Generic (ondansetron),
11.12.5. Kytril Generic (granisetron),
11.12.6. SUSTOL (extended release granisetron injection),
11.12.7. Rolapitant
11.13. U.K. CINV Existing and Pipeline Drugs Market Forecast, By End-Use
11.13.1. Hospitals
11.13.2. Specialty Clinics
11.13.3. Diagnostic Centers Therapeutics
11.13.4. Hospital Pharmacies
11.13.5. Drugstores
11.14. France CINV Existing and Pipeline Drugs Market Forecast, By Drug type
11.14.1. Akynzeo (netupitant-palonosetron),
11.14.2. Emend (aprepitant),
11.14.3. Aloxi (palonosetron),
11.14.4. Zofran Generic (ondansetron),
11.14.5. Kytril Generic (granisetron),
11.14.6. SUSTOL (extended release granisetron injection),
11.14.7. Rolapitant
11.15. France CINV Existing and Pipeline Drugs Market Forecast, By End-Use
11.15.1. Hospitals
11.15.2. Specialty Clinics
11.15.3. Diagnostic Centers Therapeutics
11.15.4. Hospital Pharmacies
11.15.5. Drugstores
11.16. Italy CINV Existing and Pipeline Drugs Market Forecast, By Drug type
11.16.1. Akynzeo (netupitant-palonosetron),
11.16.2. Emend (aprepitant),
11.16.3. Aloxi (palonosetron),
11.16.4. Zofran Generic (ondansetron),
11.16.5. Kytril Generic (granisetron),
11.16.6. SUSTOL (extended release granisetron injection),
11.16.7. Rolapitant
11.17. Italy CINV Existing and Pipeline Drugs Market Forecast, By End-Use
11.17.1. Hospitals
11.17.2. Specialty Clinics
11.17.3. Diagnostic Centers Therapeutics
11.17.4. Hospital Pharmacies
11.17.5. Drugstores
11.18. Spain CINV Existing and Pipeline Drugs Market Forecast, By Drug type
11.18.1. Akynzeo (netupitant-palonosetron),
11.18.2. Emend (aprepitant),
11.18.3. Aloxi (palonosetron),
11.18.4. Zofran Generic (ondansetron),
11.18.5. Kytril Generic (granisetron),
11.18.6. SUSTOL (extended release granisetron injection),
11.18.7. Rolapitant
11.19. Spain CINV Existing and Pipeline Drugs Market Forecast, By End-Use
11.19.1. Hospitals
11.19.2. Specialty Clinics
11.19.3. Diagnostic Centers Therapeutics
11.19.4. Hospital Pharmacies
11.19.5. Drugstores
11.20. Rest of Europe CINV Existing and Pipeline Drugs Market Forecast, By Drug type
11.20.1. Akynzeo (netupitant-palonosetron),
11.20.2. Emend (aprepitant),
11.20.3. Aloxi (palonosetron),
11.20.4. Zofran Generic (ondansetron),
11.20.5. Kytril Generic (granisetron),
11.20.6. SUSTOL (extended release granisetron injection),
11.20.7. Rolapitant
11.21. Rest of Europe CINV Existing and Pipeline Drugs Market Forecast, By End-Use
11.21.1. Hospitals
11.21.2. Specialty Clinics
11.21.3. Diagnostic Centers Therapeutics
11.21.4. Hospital Pharmacies
11.21.5. Drugstores
11.22. Europe CINV Existing and Pipeline Drugs Market Attractiveness Analysis
11.22.1. By Drug type
11.22.2. By End-Use
11.23. PEST Analysis
11.24. Key Trend
11.25. Key Development

12. Asia Pacific CINV Existing and Pipeline Drugs Market Analysis
12.1. Key Findings
12.2. Asia Pacific CINV Existing and Pipeline Drugs Market Overview
12.3. Asia Pacific CINV Existing and Pipeline Drugs Market Value Share Analysis, By Drug type
12.4. Asia Pacific CINV Existing and Pipeline Drugs Market Forecast, By Drug type
12.4.1. Akynzeo (netupitant-palonosetron),
12.4.2. Emend (aprepitant),
12.4.3. Aloxi (palonosetron),
12.4.4. Zofran Generic (ondansetron),
12.4.5. Kytril Generic (granisetron),
12.4.6. SUSTOL (extended release granisetron injection),
12.4.7. Rolapitant
12.5. Asia Pacific CINV Existing and Pipeline Drugs Market Value Share Analysis, By End-Use
12.6. Asia Pacific CINV Existing and Pipeline Drugs Market Forecast, By End-Use
12.6.1. Hospitals
12.6.2. Specialty Clinics
12.6.3. Diagnostic Centers Therapeutics
12.6.4. Hospital Pharmacies
12.6.5. Drugstores
12.7. Asia Pacific CINV Existing and Pipeline Drugs Market Value Share Analysis, by Country
12.8. Asia Pacific CINV Existing and Pipeline Drugs Market Forecast, by Country
12.8.1. China
12.8.2. India
12.8.3. Japan
12.8.4. ASEAN
12.8.5. Rest of Asia Pacific
12.9. Asia Pacific CINV Existing and Pipeline Drugs Market Analysis, by Country
12.10. China CINV Existing and Pipeline Drugs Market Forecast, By Drug type
12.10.1. Akynzeo (netupitant-palonosetron),
12.10.2. Emend (aprepitant),
12.10.3. Aloxi (palonosetron),
12.10.4. Zofran Generic (ondansetron),
12.10.5. Kytril Generic (granisetron),
12.10.6. SUSTOL (extended release granisetron injection),
12.10.7. Rolapitant
12.11. China CINV Existing and Pipeline Drugs Market Forecast, By End-Use
12.11.1. Hospitals
12.11.2. Specialty Clinics
12.11.3. Diagnostic Centers Therapeutics
12.11.4. Hospital Pharmacies
12.11.5. Drugstores
12.12. India CINV Existing and Pipeline Drugs Market Forecast, By Drug type
12.12.1. Akynzeo (netupitant-palonosetron),
12.12.2. Emend (aprepitant),
12.12.3. Aloxi (palonosetron),
12.12.4. Zofran Generic (ondansetron),
12.12.5. Kytril Generic (granisetron),
12.12.6. SUSTOL (extended release granisetron injection),
12.12.7. Rolapitant
12.13. India CINV Existing and Pipeline Drugs Market Forecast, By End-Use
12.13.1. Hospitals
12.13.2. Specialty Clinics
12.13.3. Diagnostic Centers Therapeutics
12.13.4. Hospital Pharmacies
12.13.5. Drugstores
12.14. Japan CINV Existing and Pipeline Drugs Market Forecast, By Drug type
12.14.1. Akynzeo (netupitant-palonosetron),
12.14.2. Emend (aprepitant),
12.14.3. Aloxi (palonosetron),
12.14.4. Zofran Generic (ondansetron),
12.14.5. Kytril Generic (granisetron),
12.14.6. SUSTOL (extended release granisetron injection),
12.14.7. Rolapitant
12.15. Japan CINV Existing and Pipeline Drugs Market Forecast, By End-Use
12.15.1. Hospitals
12.15.2. Specialty Clinics
12.15.3. Diagnostic Centers Therapeutics
12.15.4. Hospital Pharmacies
12.15.5. Drugstores
12.16. ASEAN CINV Existing and Pipeline Drugs Market Forecast, By Drug type
12.16.1. Akynzeo (netupitant-palonosetron),
12.16.2. Emend (aprepitant),
12.16.3. Aloxi (palonosetron),
12.16.4. Zofran Generic (ondansetron),
12.16.5. Kytril Generic (granisetron),
12.16.6. SUSTOL (extended release granisetron injection),
12.16.7. Rolapitant
12.17. ASEAN CINV Existing and Pipeline Drugs Market Forecast, By End-Use
12.17.1. Hospitals
12.17.2. Specialty Clinics
12.17.3. Diagnostic Centers Therapeutics
12.17.4. Hospital Pharmacies
12.17.5. Drugstores
12.18. Rest of Asia Pacific CINV Existing and Pipeline Drugs Market Forecast, By Drug type
12.18.1. Akynzeo (netupitant-palonosetron),
12.18.2. Emend (aprepitant),
12.18.3. Aloxi (palonosetron),
12.18.4. Zofran Generic (ondansetron),
12.18.5. Kytril Generic (granisetron),
12.18.6. SUSTOL (extended release granisetron injection),
12.18.7. Rolapitant
12.19. Rest of Asia Pacific CINV Existing and Pipeline Drugs Market Forecast, By End-Use
12.19.1. Hospitals
12.19.2. Specialty Clinics
12.19.3. Diagnostic Centers Therapeutics
12.19.4. Hospital Pharmacies
12.19.5. Drugstores
12.20. Asia Pacific CINV Existing and Pipeline Drugs Market Attractiveness Analysis
12.20.1. By Drug type
12.20.2. By End-Use
12.21. PEST Analysis
12.22. Key Trend
12.23. Key Development

13. Middle East & Africa CINV Existing and Pipeline Drugs Market Analysis
13.1. Key Findings
13.2. Middle East & Africa CINV Existing and Pipeline Drugs Market Overview
13.3. Middle East & Africa CINV Existing and Pipeline Drugs Market Value Share Analysis, By Drug type
13.4. Middle East & Africa CINV Existing and Pipeline Drugs Market Forecast, By Drug type
13.4.1. Akynzeo (netupitant-palonosetron),
13.4.2. Emend (aprepitant),
13.4.3. Aloxi (palonosetron),
13.4.4. Zofran Generic (ondansetron),
13.4.5. Kytril Generic (granisetron),
13.4.6. SUSTOL (extended release granisetron injection),
13.4.7. Rolapitant
13.5. Middle East & Africa CINV Existing and Pipeline Drugs Market Value Share Analysis, By End-Use
13.6. Middle East & Africa CINV Existing and Pipeline Drugs Market Forecast, By End-Use
13.6.1. Hospitals
13.6.2. Specialty Clinics
13.6.3. Diagnostic Centers Therapeutics
13.6.4. Hospital Pharmacies
13.6.5. Drugstores 
13.7. Middle East & Africa CINV Existing and Pipeline Drugs Market Value Share Analysis, by Country
13.8. Middle East & Africa CINV Existing and Pipeline Drugs Market Forecast, by Country
13.8.1. GCC
13.8.2. South Africa
13.8.3. Rest of Middle East & Africa
13.9. Middle East & Africa CINV Existing and Pipeline Drugs Market Analysis, by Country
13.10. GCC CINV Existing and Pipeline Drugs Market Forecast, By Drug type
13.10.1. Akynzeo (netupitant-palonosetron),
13.10.2. Emend (aprepitant),
13.10.3. Aloxi (palonosetron),
13.10.4. Zofran Generic (ondansetron),
13.10.5. Kytril Generic (granisetron),
13.10.6. SUSTOL (extended release granisetron injection),
13.10.7. Rolapitant
13.11. GCC CINV Existing and Pipeline Drugs Market Forecast, By End-Use
13.11.1. Hospitals
13.11.2. Specialty Clinics
13.11.3. Diagnostic Centers Therapeutics
13.11.4. Hospital Pharmacies
13.11.5. Drugstores
13.12. South Africa CINV Existing and Pipeline Drugs Market Forecast, By Drug type
13.12.1. Akynzeo (netupitant-palonosetron),
13.12.2. Emend (aprepitant),
13.12.3. Aloxi (palonosetron),
13.12.4. Zofran Generic (ondansetron),
13.12.5. Kytril Generic (granisetron),
13.12.6. SUSTOL (extended release granisetron injection),
13.12.7. Rolapitant
13.13. South Africa CINV Existing and Pipeline Drugs Market Forecast, By End-Use
13.13.1. Hospitals
13.13.2. Specialty Clinics
13.13.3. Diagnostic Centers Therapeutics
13.13.4. Hospital Pharmacies
13.13.5. Drugstores
13.14. Rest of Middle East & Africa CINV Existing and Pipeline Drugs Market Forecast, By Drug type
13.14.1. Akynzeo (netupitant-palonosetron),
13.14.2. Emend (aprepitant),
13.14.3. Aloxi (palonosetron),
13.14.4. Zofran Generic (ondansetron),
13.14.5. Kytril Generic (granisetron),
13.14.6. SUSTOL (extended release granisetron injection),
13.14.7. Rolapitant
13.15. Rest of Middle East & Africa CINV Existing and Pipeline Drugs Market Forecast, By End-Use
13.15.1. Hospitals
13.15.2. Specialty Clinics
13.15.3. Diagnostic Centers Therapeutics
13.15.4. Hospital Pharmacies
13.15.5. Drugstores
13.16. Middle East & Africa CINV Existing and Pipeline Drugs Market Attractiveness Analysis
13.16.1. By Drug type
13.16.2. By End-Use
13.17. PEST Analysis
13.18. Key Trend
13.19. Key Development

14. South America CINV Existing and Pipeline Drugs Market Analysis
14.1. Key Findings
14.2. South America CINV Existing and Pipeline Drugs Market Overview
14.3. South America CINV Existing and Pipeline Drugs Market Value Share Analysis, By Drug type
14.4. South America CINV Existing and Pipeline Drugs Market Forecast, By Drug type
14.4.1. Akynzeo (netupitant-palonosetron),
14.4.2. Emend (aprepitant),
14.4.3. Aloxi (palonosetron),
14.4.4. Zofran Generic (ondansetron),
14.4.5. Kytril Generic (granisetron),
14.4.6. SUSTOL (extended release granisetron injection),
14.4.7. Rolapitant
14.5. South America CINV Existing and Pipeline Drugs Market Value Share Analysis, By End-Use
14.6. South America CINV Existing and Pipeline Drugs Market Forecast, By End-Use
14.6.1. Hospitals
14.6.2. Specialty Clinics
14.6.3. Diagnostic Centers Therapeutics
14.6.4. Hospital Pharmacies
14.6.5. Drugstores
14.7. South America CINV Existing and Pipeline Drugs Market Value Share Analysis, by Country
14.8. South America CINV Existing and Pipeline Drugs Market Forecast, by Country
14.8.1. Brazil
14.8.2. Mexico
14.8.3. Rest of South America
14.9. Brazil CINV Existing and Pipeline Drugs Market Forecast, By Drug type
14.9.1. Akynzeo (netupitant-palonosetron),
14.9.2. Emend (aprepitant),
14.9.3. Aloxi (palonosetron),
14.9.4. Zofran Generic (ondansetron),
14.9.5. Kytril Generic (granisetron),
14.9.6. SUSTOL (extended release granisetron injection),
14.9.7. Rolapitant
14.10. Brazil CINV Existing and Pipeline Drugs Market Forecast, By End-Use
14.10.1. Hospitals
14.10.2. Specialty Clinics
14.10.3. Diagnostic Centers Therapeutics
14.10.4. Hospital Pharmacies
14.10.5. Drugstores
14.11. Mexico CINV Existing and Pipeline Drugs Market Forecast, By Drug type
14.11.1. Akynzeo (netupitant-palonosetron),
14.11.2. Emend (aprepitant),
14.11.3. Aloxi (palonosetron),
14.11.4. Zofran Generic (ondansetron),
14.11.5. Kytril Generic (granisetron),
14.11.6. SUSTOL (extended release granisetron injection),
14.11.7. Rolapitant
14.12. Mexico CINV Existing and Pipeline Drugs Market Forecast, By End-Use
14.12.1. Hospitals
14.12.2. Specialty Clinics
14.12.3. Diagnostic Centers Therapeutics
14.12.4. Hospital Pharmacies
14.12.5. Drugstores
14.13. Rest of South America CINV Existing and Pipeline Drugs Market Forecast, By Drug type
14.13.1. Akynzeo (netupitant-palonosetron),
14.13.2. Emend (aprepitant),
14.13.3. Aloxi (palonosetron),
14.13.4. Zofran Generic (ondansetron),
14.13.5. Kytril Generic (granisetron),
14.13.6. SUSTOL (extended release granisetron injection),
14.13.7. Rolapitant
14.14. Rest of South America CINV Existing and Pipeline Drugs Market Forecast, By End-Use
14.14.1. Hospitals
14.14.2. Specialty Clinics
14.14.3. Diagnostic Centers Therapeutics
14.14.4. Hospital Pharmacies
14.14.5. Drugstores
14.15. South America CINV Existing and Pipeline Drugs Market Attractiveness Analysis
14.15.1. By Drug type
14.15.2. By End-Use
14.16. PEST Analysis
14.17. Key Trend
14.18. Key Development

15. Company Profiles
15.1. Market Share Analysis, by Company
15.2. Competition Matrix
15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
15.2.2. New Drug type Launches and Drug type Enhancements
15.2.3. Market Consolidation
15.2.3.1. M&A by Regions, Investment and Applications
15.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
15.3. Company Profiles: Key Players
15.3.1. GlaxoSmithKline
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Drug type Portfolio
15.3.1.4. Business Strategy
15.3.1.5. Recent Developments
15.3.1.6. Company Footprint
15.3.2. Helsinn
15.3.3. Heron Therapeutics
15.3.4. Merck
15.3.5. Tesaro
15.3.6. Eastman
15.3.7. Lonza
15.3.8. CHEMIDEA CHEMICALS
15.3.9. Teva pharmaceutical
15.3.10. Baxter Healthcare,
15.3.11. Sun Pharma,
15.3.12. Mylan Pharmaceuticals, Inc.,
15.3.13. Sandoz (Novartis AG),
15.3.14. Barr Laboratories, Inc.
15.3.15. Orchid Healthcare
15.3.16. Acacia Pharma
15.3.17. TALLC Corporation
15.3.18. LP Pharmaceuticals

16. Primary Key Insights
  • INQUIRE BEFORE BUYING